ArticleACS omega2025
Synthesis, Characterization, and Toxicity Assessment of Superparamagnetic Iron Oxide Nanoparticles Coated with Antitumor Molecules.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New definitions describe cancer as a condition where cells, transformed by natural selection, undergo uncontrolled proliferation. Currently, several available drugs for treating cancer present side effects and are nonselective, thus complicating patient treatment. To overcome such issues, alternative therapies using inorganic nanoparticles and parent compounds are becoming more attractive. Here, we demonstrate the use of biocompatible superparamagnetic iron oxide nanoparticles (SPIONs) coated with the LASSBio-1735 parent compound in BALB/c mice inoculated with the Ehrlich tumor. We first characterize the formed nanoparticles and confirm and quantify the anchoring of LASSBio-1735 on the surface of the SPIONs. Tests conducted after 7, 14, and 30 days show that no significant alterations were found in erythrocyte count analysis, hemoglobin and hematocrit determination, platelet and leukocyte counts, neutrophil/lymphocyte ratio, serum iron dosage, alanine aminotransferase, aspartate aminotransferase, serum creatinine, and urea determination, as well as analysis of the animals' and tumor weights. This confirms that this new alternative can be considered in clinical trials to treat solid tumors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.